Table 3. Specificity and Positive Predictive Value

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Screening: Breast Cancer > Summary of the Evidence

Table 3. Specificity and Positive Predictive Value^a

Study	Specificity (%) (Work-up method)	Positive Predictive Value (%) (Work-up method)	Positive Predictive Value (%) (Biopsy method)
HIP	NR	12	20
Malmö	97.4	10-22	33-61
Swedish Two-County Trial	95.6	12	50-75
Stockholm	95.1	8-10	62-78
CNBSS-1	93.5	2	12
CNBSS-2		4-6	20
Gothenburg		3-7 (complete mammography) 12-18 (CBE and FNA biopsy)

^aAdapted from references 36 and 45. Work-up method, a mammogram requiring further evaluation; biopsy method, a mammogram resulting in biopsy.

Note: CBE indicates clinical breast examination; CNBSS, Canadian National Breast Screening Study; FNA, fine-needle aspiration; HIP, Health Insurance Plan of Greater New York; NR, not reported.

Return to Document

Table 3. Specificity and Positive Predictive Valuea

Table 3. Specificity and Positive Predictive Value^a